# Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

## How to use the child/adolescent immunization schedule

1. **Determine recommended vaccine by age** (Table 1)
2. **Determine recommended interval for catch-up vaccination** (Table 2)
3. **Assess need for additional recommended vaccines by medical condition and other indications** (Table 3)
4. **Review vaccine types, frequencies, intervals, and considerations for special situations** (Notes)

**Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Assistants (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).**

## Vaccines in the Child and Adolescent Immunization Schedule*

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Abbreviations</th>
<th>Trade names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis vaccine</td>
<td>DTaP</td>
<td>Daptacel® Infanrix*</td>
</tr>
<tr>
<td>Diphtheria, tetanus vaccine</td>
<td>DT</td>
<td>No trade name</td>
</tr>
<tr>
<td>Haemophilus influenzae type b vaccine</td>
<td>Hib (PRP-T)</td>
<td>ActHIB® Hibexrix® PedvaxHIB*</td>
</tr>
<tr>
<td></td>
<td>Hib (PRP-OMP)</td>
<td>Hibrix® Vbrig*</td>
</tr>
<tr>
<td>Hepatitis A vaccine</td>
<td>HepA</td>
<td>Havrix® Vaqta*</td>
</tr>
<tr>
<td>Hepatitis B vaccine</td>
<td>HepB</td>
<td>Engerix-B® Recombivax HB*</td>
</tr>
<tr>
<td>Human papillomavirus vaccine</td>
<td>HPV</td>
<td>Gardasil® 9*</td>
</tr>
<tr>
<td>Influenza vaccine (inactivated)</td>
<td>IIV</td>
<td>MultiplE</td>
</tr>
<tr>
<td>Influenza vaccine (live, attenuated)</td>
<td>LAIV4</td>
<td>FluMist® Quadrivalent</td>
</tr>
<tr>
<td>Measles, mumps, and rubella vaccine</td>
<td>MMR</td>
<td>M-M-R II®</td>
</tr>
<tr>
<td>Meningococcal serogroups A, C, W, Y vaccine</td>
<td>MenACWY-D</td>
<td>Menactra®</td>
</tr>
<tr>
<td></td>
<td>MenACWY-CRM</td>
<td>Menevo®</td>
</tr>
<tr>
<td></td>
<td>MenACWY-TT</td>
<td>MenQuad®</td>
</tr>
<tr>
<td>Meningococcal serogroup B vaccine</td>
<td>MenB-4C</td>
<td>Bexsero®</td>
</tr>
<tr>
<td></td>
<td>MenB-FHbp</td>
<td>Trumena®</td>
</tr>
<tr>
<td>Pneumococcal 13-valent conjugate vaccine</td>
<td>PCV13</td>
<td>Prevnar 13®</td>
</tr>
<tr>
<td>Pneumococcal 23-valent polysaccharide vaccine</td>
<td>PPSV23</td>
<td>Pneumovax 23®</td>
</tr>
<tr>
<td>Poliovirus vaccine (inactivated)</td>
<td>IPV</td>
<td>IPOL®</td>
</tr>
<tr>
<td>Rotavirus vaccine</td>
<td>RV1</td>
<td>Rotarix® Rotasoft®</td>
</tr>
<tr>
<td></td>
<td>RV5</td>
<td>Rotarix® Rotasoft®</td>
</tr>
<tr>
<td>Tetanus, diphtheria, and acellular pertussis vaccine</td>
<td>Tdap</td>
<td>Adacel® Boostrix®</td>
</tr>
<tr>
<td>Tetanus and diphtheria vaccine</td>
<td>Td</td>
<td>Tenivac® TdVacTM</td>
</tr>
<tr>
<td>Varicella vaccine</td>
<td>VAR</td>
<td>Varivax®</td>
</tr>
</tbody>
</table>

**Combination vaccines (use combination vaccines in stead of separate injections when appropriate)**

| DTaP, hepatitis B, and inactivated poliovirus vaccine | DTaP-HepB-IPV | Pediarix® |
| DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine | DTaP-IPV/Hib | Pentacel® |
| DTaP and inactivated poliovirus vaccine | DTaP-IPV | Kinrix® Quadrix® |
| DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine | DTaP-IPV-Hib-HepB | Vaxelis® |
| Measles, mumps, rubella, and varicella vaccine | MMRV | ProQuad® |

---

*Administrated recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

---

**Report**
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

**Helpful information**
- Complete ACIP recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Outbreak information (including case identification and outbreak response), see Manual for the Surveillance of Vaccine-Preventable Diseases: www.cdc.gov/vaccines/pubs/surv-manual

---

**U.S. Department of Health and Human Services**
**Centers for Disease Control and Prevention**
Table 1: Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars.

To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are shaded in gray.

<table>
<thead>
<tr>
<th>Vaccine Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16 yrs</th>
<th>17-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatitis B (HepB)</strong></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
<td>16th dose</td>
</tr>
<tr>
<td><strong>Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)</strong></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
<td>16th dose</td>
</tr>
<tr>
<td><strong>Diphtheria, tetanus, acellular pertussis (DTaP &lt;7 yrs)</strong></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td><strong>Haemophilus influenzae type b (Hib)</strong></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd or 4th dose</td>
<td>See Notes</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td><strong>Pneumococcal conjugate (PCV13)</strong></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
<td>16th dose</td>
</tr>
<tr>
<td><strong>Inactivated poliovirus (IPV &lt;18 yrs)</strong></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td>Annual vaccination 1 or 2 doses</td>
<td>Annual vaccination 1 or 2 doses</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
</tr>
<tr>
<td>Influenza (LAIV4)</td>
<td>Annual vaccination 1 dose only</td>
<td>Annual vaccination 1 dose only</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
<td>16th dose</td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2 years)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Meningococcal B</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>See Notes</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td>6th dose</td>
<td>7th dose</td>
<td>8th dose</td>
<td>9th dose</td>
<td>10th dose</td>
<td>11th dose</td>
<td>12th dose</td>
<td>13th dose</td>
<td>14th dose</td>
<td>15th dose</td>
</tr>
</tbody>
</table>

- **Range of recommended ages for all children**
- **Range of recommended ages for catch-up immunization**
- **Range of recommended ages for certain high-risk groups**
- **Recommended based on shared clinical decision-making or**
- **can be used in this age group**
- **No recommendation/not applicable**
### Table 2
Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 month Behind, United States, 2021

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. **Always use this table in conjunction with Table 1 and the notes that follow.**

#### Children age 4 months through 6 years

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Dose 1 to Dose 2</th>
<th>Minimum Interval Between Doses</th>
<th>Dose 3 to Dose 4</th>
<th>Dose 4 to Dose 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>Birth</td>
<td>4 weeks</td>
<td>8 weeks and at least 16 weeks after first dose. Minimum age for the final dose is 24 weeks.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>4 weeks</td>
<td>Maximum age for final dose is 8 months, 0 days.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum age for first dose is 14 weeks, 6 days.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>6 weeks</td>
<td>No further doses needed if first dose was administered before the 1st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months.</td>
<td>No further doses needed if previous dose was administered at age 15 months or older. 4 weeks if current age is younger than 12 months and first dose was administered before younger than 7 months old and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberox) or unknown. 8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 59 months and first dose was administered before the 1st birthday and second dose was administered at younger than 15 months; OR if both doses were PRP-OMP (PedvaxHIB, Comvax) and were administered before the 1st birthday.</td>
<td>8 weeks (as final dose) if current age is 12 through 59 months and received 3 doses before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 weeks</td>
<td>4 weeks</td>
<td></td>
<td>6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6 weeks</td>
<td>No further doses needed for healthy children if first dose was administered at age ≥24 months or older. 4 weeks if first dose was administered before the 1st birthday. 8 weeks (as final dose for healthy children) if first dose was administered at the 1st birthday or after.</td>
<td>No further doses needed for healthy children if previous dose was administered at age ≥24 months or older. 4 weeks if current age is younger than 12 months and previous dose was administered at &lt;7 months old. 8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months.</td>
<td>8 weeks (as final dose) if current age is 12 through 59 months and received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>4 weeks if current age is &lt;4 years. 6 months (as final dose) if current age is 4 years or older.</td>
<td>6 months (minimum age 4 years for final dose).</td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td>4 weeks</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td>3 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>2 months MenACWY: CRM 9 months MenACWY:D 2 years MenACWYT 8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>Not applicable (N/A)</td>
<td>8 weeks</td>
<td>4 weeks if first dose of DTaP/DT was administered before the 1st birthday. 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.</td>
<td>6 months if first dose of DTaP/ DT was administered before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>9 years</td>
<td>Routine dosing intervals are recommended.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>N/A</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>N/A</td>
<td>4 weeks</td>
<td>8 weeks and at least 16 weeks after first dose. 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>N/A</td>
<td>4 weeks</td>
<td>A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>N/A</td>
<td>4 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>N/A</td>
<td>4 weeks if younger than age 13 years. 3 months if age 13 years or older.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Children and adolescents age 7 through 18 years

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Dose 1 to Dose 2</th>
<th>Minimum Interval Between Doses</th>
<th>Dose 3 to Dose 4</th>
<th>Dose 4 to Dose 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, diphtheria, and acellular pertussis</td>
<td>7 years</td>
<td>4 weeks</td>
<td>4 weeks if first dose of DTaP/DT was administered before the 1st birthday. 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.</td>
<td>6 months if first dose of DTaP/ DT was administered before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>9 years</td>
<td>Routine dosing intervals are recommended.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>N/A</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>N/A</td>
<td>4 weeks</td>
<td>8 weeks and at least 16 weeks after first dose. 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>N/A</td>
<td>4 weeks</td>
<td>A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>N/A</td>
<td>4 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>N/A</td>
<td>3 months if younger than age 13 years. 4 weeks if age 13 years or older.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VACCINE</td>
<td>INDICATION</td>
<td>PREGNANCY</td>
<td>IMMUNOCOMPROMISED STATUS (EXCLUDING HIV INFECTION)</td>
<td>HIV INFECTION CD4+ COUNT</td>
<td>KIDNEY FAILURE, END-STAGE RENAL DISEASE, OR ON HEMODIALYSIS</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------</td>
<td>--------------------------------------------------</td>
<td>--------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis (DTaP)</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td></td>
<td></td>
<td>Not recommended/contraindicated—vaccine should not be administered.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (LAIV4)</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, and acellular pertussis (Tdap)</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide</td>
<td></td>
<td></td>
<td>Is indicated if benefit of protection outweighs risk of adverse reaction.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, “Altered Immunocompetence,” at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (footnote D) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.
2 Severe Combined Immunodeficiency
3 LAIV4 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months.
Notes
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021

Additional information

COVID-19 Vaccination
ACIP recommends use of COVID-19 vaccines within the scope of the Emergency Use Authorization or Biologics License Application for the particular vaccine. Interim ACIP recommendations for the use of COVID-19 vaccines can be found at www.cdc.gov/vaccines/hcp/acip-recs/

• Consult relevant ACIP statements for detailed recommendations at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
• For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html and relevant ACIP statements at www.cdc.gov/vaccines/hcp/acip-recs/v/index.html.
• For calculating intervals between doses, 4 weeks = 28 days. Interval of ≥4 months are determined by calendar months.
• Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
• Vaccine doses administered ≥4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
• Information on travel vaccination requirements and recommendations is available at www.cdc.gov/travel/.
• For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.html.

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks (4 years for Kinrix or Quadracel))

Routine vaccination
• 5-dose series at 2, 4, 6, 15–18 months, 4–6 years
  - Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
  - Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

Catch-up vaccination
• Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
• For other catch-up guidance, see Table 2.

Special situations
• Wound management in children less than age 7 years with history of 3 or more doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/mm6702a1.htm.

Haemophilus influenzae type b vaccination (minimum age: 6 weeks)

Routine vaccination
• ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 6, 12–13 months
• PedvaxHIB: 3-dose series at 2, 4, 12–15 months

Catch-up vaccination
• Dose 1 at age 7–11 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).
• Dose 1 at age 12–14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.
• Dose 1 before age 12 months and dose 2 before age 15 months: Administer dose 3 (final dose) 8 weeks after dose 2.
• 2 doses of PedvaxHIB before age 12 months: Administer dose 3 (final dose) at 12–59 months and at least 8 weeks after dose 2.
• 1 dose administered at age 15 months or older: No further doses needed
• Unvaccinated at age 15–59 months: Administer 1 dose.
• Previously unvaccinated children age 60 months or older who are not considered high risk: Do not require catch-up vaccination
• For other catch-up guidance, see Table 2.

Special situations
• Chemotherapy or radiation treatment: 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
• Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.
• Hematopoietic stem cell transplant (HSCT): 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant, regardless of Hib vaccination history
• Anatomic or functional asplenia (including sickle cell disease): 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
• Unvaccinated* persons age 5 years or older
  - 1 dose
• Elective splenectomy: Unvaccinated* persons age 15 months or older
  - 1 dose (preferably at least 14 days before procedure)
• HIV infection: 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
• Unvaccinated* persons age 5–18 years
  - 1 dose
• Immunoglobulin deficiency, early component complement deficiency: 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
• Unvaccinated* = Less than routine series (through age 14 months) OR no doses (age 15 months or older)
**Notes**

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021**

### Hepatitis A vaccination

**Minimum age:** 12 months for routine vaccination

#### Routine vaccination

- 2-dose series (minimum interval: 6 months) beginning at age 12 months

#### Catch-up vaccination

- Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
- Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
- Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix® (as a 3-dose series (0, 1, and 6 months)) or 4-dose series (3 doses at 0, 1, and 21–30 days, followed by a booster dose at 12 months).

### International travel

- Persons traveling to or working in countries with high or intermediate endemic hepatitis A (www.cdc.gov/travel):
  - Infants age 6–11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between age 12–23 months.
  - Unvaccinated age 12 months or older: Administer dose 1 as soon as travel is considered.

### Hepatitis B vaccination

**Minimum age:** birth

#### Birth dose (monovalent HepB vaccine only)

- Mother is HBsAg-negative: 1 dose within 24 hours of birth for all medically stable infants ≥2,000 grams. Infants <2,000 grams: Administer 1 dose at chronological age 1 month or hospital discharge (whichever is earlier and even if weight is still <2,000 grams).
- Mother is HBsAg-positive:
  - Administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
  - Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.
- Mother’s HBsAg status is unknown:
  - Administer HepB vaccine within 12 hours of birth, regardless of birth weight.
  - For infants <2,000 grams, administer HBIG in addition to HepB vaccine (in separate limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
  - Determine mother’s HBsAg status as soon as possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.

#### Routine series

- 3-dose series at 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks)
- Infants who did not receive a birth dose should begin the series as soon as feasible (see Table 2).
- Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.

### Influenza vaccination

**Minimum age:** 6 months (IIV), 2 years (LAIV4), 18 years (recombinant influenza vaccine, RIV4)

#### Routine vaccination

- Use any influenza vaccine appropriate for age and health status annually:
  - 2 doses, separated by at least 4 weeks, for children age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2020, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2).
  - 1 dose for children age 6 months–8 years who have received at least 2 influenza vaccine doses before July 1, 2020.
  - 1 dose for all persons age 9 years or older.
- For the 2021–22 season, see the 2021–22 ACIP influenza vaccine recommendations.

#### Special situations

- **Egg allergy, hives only:** Any influenza vaccine appropriate for age and health status annually
- **Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress, need for emergency medical services or epinephrine):** Any influenza vaccine appropriate for age and health status annually. If using an influenza vaccine other than Flublok or Flucelvax, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions.
- **Severe allergic reactions to vaccines can occur even in the absence of a history of previous allergic reaction.** All vaccination providers should be familiar with the office emergency plan and certified in cardiopulmonary resuscitation.
- **A previous severe allergic reaction to influenza vaccine is a contraindication to future receipt of any influenza vaccine.**
- **LAIV4 should not be used** in persons with the following conditions or situations:
  - History of severe allergic reaction to a previous dose of any influenza vaccine or to any vaccine component (excluding egg, see details above)
  - Receiving aspirin or salicylate-containing medications
  - Age 2–4 years with history of asthma or wheezing
  - Immunosuppressed due to any cause (including medications and HIV infection)
  - Anatomical or functional asplenia
  - Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
  - Pregnancy
  - Cochlear implant
  - Cerebro spinal fluid–oropharyngeal communication
  - Children less than age 2 years
  - Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days

### Human papillomavirus vaccination

**Minimum age:** 9 years

#### Routine and catch-up vaccination

- HPV vaccination routinely recommended at age 11–12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
- 2- or 3-dose series depending on age at initial vaccination:
  - Age 9–14 years at initial vaccination: 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
  - Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 24 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon)
- Interrupted schedules: If vaccination schedule is interrupted, the series does not need to be restarted.
- No additional dose recommended after completing series with recommended dosing intervals using any HPV vaccine.

### Special situations

- **Immunocompromising conditions, including HIV infection:** 3-dose series as above
- **History of sexual abuse or assault:** Start at age 9 years.
- **Pregnancy:** HPV vaccination not recommended until earlier than pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination.

---

**3-7**
**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States 2021**

**MenQuadrix**
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
- Less than 3 PCV13 doses: 2 doses PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)
- At least 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)

**Menveo**
- Unvaccinated children age 12 months or older:
  - 1 dose for healthy children age 24–59 months with any underlying conditions below: When both PCV13 and PPSV23 were completed and given at recommended ages (minimum interval: 8 weeks)
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose of PCV13 and administered 8 weeks apart)

**Menactra**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**Menveo (age 2–23 months)**
- 2-dose series at least 1 month apart

**Bexsero**
- 2-dose series at 12–15 months, 4–6 years

**Notes**
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks after any prior dose and administered 8 weeks apart
- At least 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)

**MenQuadrix**
- For MenQuadrix:
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose of PCV13 and administered 8 weeks apart)

**Menactra**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**Menmev (age 2–5 years)**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**Menactra**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**MenQuadrix**
- For MenQuadrix:
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose of PCV13 and administered 8 weeks apart)

**Menactra**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**Menmev (age 2–5 years)**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**MenQuadrix**
- For MenQuadrix:
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose of PCV13 and administered 8 weeks apart)

**Menactra**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**Menmev (age 2–5 years)**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**MenQuadrix**
- For MenQuadrix:
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior dose and administered 8 weeks apart)
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose of PCV13 and administered 8 weeks apart)

**Menactra**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months

**Menmev (age 2–5 years)**
- Unvaccinated children who live in residential settings for meningococcal disease, including countries in the African meningitis belt or during the Hajj:
  - 3-dose series at 0, 1–2, 6 months
Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:  
Age 2–5 years  
• Any incomplete* series with:  
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)  
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)  
• No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a 2nd dose of PPSV23 5 years later  
Age 6–18 years  
• No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)  
• Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)  
• PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a 2nd dose of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13  
Chronic liver disease, alcoholism:  
Age 6–18 years  
• No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)  

Notes

Catch-up vaccination  
• In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.  
• IPV is not routinely recommended for U.S. residents age 18 years or older.  

Series containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only series:  
• Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. See www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_cid=mm6601a6_w.  
• Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements.  
  - Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign).  
  - For guidance to assess doses documented as “OPV” see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?_cid=mm6606a7_w.  
• For other catch-up guidance, see Table 2.

Rotavirus vaccination (minimum age: 6 weeks)

Routine vaccination  
• Rotarix: 2-dose series at 2 and 4 months  
• RotaTeq: 3-dose series at 2, 4, and 6 months  
• If any dose in the series is either Rotarix or unknown, default to 3-dose series.

Catch-up vaccination  
• Do not start the series on or after age 15 weeks, 0 days.  
• The maximum age for the final dose is 8 months, 0 days.  
• For other catch-up guidance, see Table 2.

Varicella vaccination (minimum age: 12 months)

Routine vaccination  
• 2-dose series at 12–15 months, 4–6 years  
• Dose 2 may be administered as early as 3 months after dose 1 (a dose administered after a 4-week interval may be counted).

Catch-up vaccination  
• Ensure persons age 7–18 years without evidence of immunity (see MMWR at www.cdc.gov/mmwr/pdf/rr/rr5911.pdf) have a 2-dose series:  
  - Age 7–12 years: routine interval: 3 months (a dose administered after a 4-week interval may be counted)  
  - Age 13 years and older: routine interval: 4–8 weeks (minimum interval: 4 weeks)  
• The maximum age for use of MMRV is 12 years.